These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 29434642)

  • 61. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
    Tapscott T; Guarnieri MT; Henard CA
    Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
    [TBL] [Abstract][Full Text] [Related]  

  • 62. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 63. CRISPR-Cas9: a new and promising player in gene therapy.
    Xiao-Jie L; Hui-Ying X; Zun-Ping K; Jin-Lian C; Li-Juan J
    J Med Genet; 2015 May; 52(5):289-96. PubMed ID: 25713109
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genome Editing by CRISPR/Cas9 in Sorghum Through Biolistic Bombardment.
    Liu G; Li J; Godwin ID
    Methods Mol Biol; 2019; 1931():169-183. PubMed ID: 30652290
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Genome-editing approaches and applications: a brief review on CRISPR technology and its role in cancer.
    Siva N; Gupta S; Gupta A; Shukla JN; Malik B; Shukla N
    3 Biotech; 2021 Mar; 11(3):146. PubMed ID: 33732568
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CRISPR: a promising tool for lipid physiology and therapeutics.
    Furgurson M; Lagor WR
    Curr Opin Lipidol; 2019 Jun; 30(3):172-176. PubMed ID: 30893109
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CRISPR/Cascade 9-Mediated Genome Editing-Challenges and Opportunities.
    Roy B; Zhao J; Yang C; Luo W; Xiong T; Li Y; Fang X; Gao G; Singh CO; Madsen L; Zhou Y; Kristiansen K
    Front Genet; 2018; 9():240. PubMed ID: 30026755
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Applications of CRISPR/Cas9 in retinal degenerative diseases.
    Peng YQ; Tang LS; Yoshida S; Zhou YD
    Int J Ophthalmol; 2017; 10(4):646-651. PubMed ID: 28503441
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CRISPR/Cas9 therapeutics for liver diseases.
    Aravalli RN; Steer CJ
    J Cell Biochem; 2018 Jun; 119(6):4265-4278. PubMed ID: 29266637
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing.
    Manghwar H; Lindsey K; Zhang X; Jin S
    Trends Plant Sci; 2019 Dec; 24(12):1102-1125. PubMed ID: 31727474
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells.
    Lee CM; Zhu H; Davis TH; Deshmukh H; Bao G
    Methods Mol Biol; 2017; 1498():3-21. PubMed ID: 27709565
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications.
    Cheng H; Zhang F; Ding Y
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683943
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of gene editing efficiencies of CRISPR/Cas9 and TALEN for generation of MSTN knock-out cashmere goats.
    Zhang J; Liu J; Yang W; Cui M; Dai B; Dong Y; Yang J; Zhang X; Liu D; Liang H; Cang M
    Theriogenology; 2019 Jul; 132():1-11. PubMed ID: 30981084
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CRISPR/Cas9, the Powerful New Genome-Editing Tool for Putative Therapeutics in Obesity.
    Franco-Tormo MJ; Salas-Crisostomo M; Rocha NB; Budde H; Machado S; Murillo-Rodríguez E
    J Mol Neurosci; 2018 May; 65(1):10-16. PubMed ID: 29732484
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genome Editing Technology: A New Frontier for the Treatment and Prevention of Cardiovascular Diseases.
    Saeed S; Khan SU; Khan WU; Abdel-Maksoud MA; Mubarak AS; Aufy M; Kiani FA; Wahab A; Shah MW; Saleem MH
    Curr Probl Cardiol; 2023 Jul; 48(7):101692. PubMed ID: 36898595
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CRISPR/Cas9 for genome editing: progress, implications and challenges.
    Zhang F; Wen Y; Guo X
    Hum Mol Genet; 2014 Sep; 23(R1):R40-6. PubMed ID: 24651067
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Analysis of microsatellite instability in CRISPR/Cas9 editing mice.
    Huo X; Du Y; Lu J; Guo M; Li Z; Zhang S; Li X; Chen Z; Du X
    Mutat Res; 2017 Mar; 797-799():1-6. PubMed ID: 28284774
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Seamless genome editing in Drosophila by combining CRISPR/Cas9 and piggyBac technologies].
    Wang J; Huang J; Xu R
    Yi Chuan; 2019 May; 41(5):422-429. PubMed ID: 31106778
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cutting Edge Genetics: CRISPR/Cas9 Editing of Plant Genomes.
    Soyars CL; Peterson BA; Burr CA; Nimchuk ZL
    Plant Cell Physiol; 2018 Aug; 59(8):1608-1620. PubMed ID: 29912402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.